Engflag

Ascoril-D Plus

Quick links to important sections

Ascoril-D Plus

Ascoril-D Plus_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ascoril-D Plus

Property Description
Active Ingredients Dextromethorphan, Menthol, Phenylpropanolamine, Triprolidine
Form Oral Liquid (Syrup)
Pharmacological Class Fixed-Dose Combination (FDC) Antitussive/Decongestant/Antihistamine
Common Use Symptomatic relief of common cold and upper respiratory symptoms
Origin Primarily Synthetic, with naturally derived component (Menthol)

What Type of Medicine is Ascoril-D Plus?

Ascoril-D Plus is a Fixed-Dose Combination (FDC) preparation classified as a multi-ingredient cough and cold preparation, delivered as an oral liquid or syrup. It falls into the high-level pharmacological class of combined agents, specifically acting as an antitussive, a nasal decongestant, and a first-generation antihistamine.

This preparation represents a single solution engineered to provide broad-spectrum symptomatic relief for the concurrent distresses associated with upper respiratory tract conditions and the common cold. The FDC approach is utilized to simultaneously address multiple symptoms such as cough, congestion, and allergic responses. This design is clinically recognized for providing consolidated management of the symptom cluster often present during a cold, simplifying the process of seeking relief.

The Multi-Component Composition and Origin

The formulation’s core contains four distinct active ingredients: Dextromethorphan, Menthol, Phenylpropanolamine, and Triprolidine. These chemical substances are stabilized and delivered in an aqueous or hydroalcoholic syrup base.

The preparation’s origin/type is a mix, featuring agents that are primarily synthetic in origin, such as the cough suppressant Dextromethorphan and the decongestant Phenylpropanolamine, alongside the naturally derived palliative component, Menthol. The inclusion of Phenylpropanolamine and the first-generation Triprolidine distinguishes this specific composition from formulations that may utilize newer, non-sedating antihistamines or alternative decongestants. Dextromethorphan's primary role as a cough suppressant confirms its classification as an antitussive. This means the medicine is designed to block the nerve signals that trigger a dry cough.

How the Combination Provides Symptomatic Relief

The general therapeutic purpose of this combination drug is to alleviate the most intrusive signs of respiratory illness, allowing the patient temporary ease. For example, a typical use scenario is to manage the persistent, dry cough and accompanying nasal blockage that interfere with normal daily activity.

By combining an antitussive (Dextromethorphan) for quieting coughs, a decongestant (Phenylpropanolamine) for opening nasal airways, and an antihistamine (Triprolidine) for controlling runny nose and sneezing, the formulation delivers a coordinated response against the cluster of common cold symptoms. The integrated action is pharmacologically supported to reduce symptom intensity across multiple pathways.

Regulatory References

  1. NIH MedlinePlus: Cold and Cough Medicines
  2. Dextromethorphan - StatPearls - NIH Bookshelf

What side effects are possible with Ascoril-D Plus?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics for this combination medicine, as classified by government regulatory authorities.

Frequency-Classified Adverse Reactions

The profile of possible effects is primarily driven by the central nervous system (CNS) active components. Regulatory documents categorize the following effects based on incidence:

  • Common: Adverse reactions frequently reported include sedation, drowsiness, dry mouth, headache, nausea, and vomiting.
  • Rare or Frequency Not Known: These include excitement, insomnia, hallucinations, convulsion or seizures, tachycardia (increased heart rate), and urinary retention.

Serious Safety Considerations

The most serious safety constraint relates to the Phenylpropanolamine (PPA) component. Regulatory agencies, including the FDA, have documented an association between PPA use and an increased risk of hemorrhagic stroke (bleeding in the brain). This critical, rare risk led the FDA to withdraw PPA's generally recognized as safe and effective status. Furthermore, Hypertensive Crisis is a high-level safety consequence documented when the medicine is used concomitantly with Monoamine Oxidase Inhibitors (MAOIs), leading to a strict contraindication.

Safety Notes for Specific Populations and Exposure

Official labels advise particular caution in specific patient groups:

  • Hepatic and Renal Impairment: Caution is noted for individuals with severe hepatic (liver) or renal (kidney) impairment due to the potential for reduced clearance of the medicine from the body.
  • Children: Excitement or excitability is a more frequently observed reaction in the pediatric population.
  • Exposure Pattern: Drowsiness may be more prominent at the beginning of treatment.

Overdose and Emergency Response

Overdose and when to seek help

The officially documented overdose profile for this combination product is primarily defined by the central nervous system (CNS) and cardiovascular effects of its active components. Overdose manifestations documented in regulatory sources range from signs of CNS depression—such as drowsiness, dizziness, and confusion—to CNS excitation, which may present as hallucinations, agitation, and potentially lead to seizures or coma. The cardiovascular system may exhibit tachycardia, hypertension, and arrhythmias.

Official Emergency Actions and Severe Outcomes

Domain Regulatory Documentation
Severe Outcomes The potential for life-threatening events, including respiratory collapse and hemorrhagic stroke, is noted in official documentation.
Mandatory Action Regulators strictly mandate that individuals seek immediate medical attention or get emergency medical help at once if an overdose is suspected.
Supportive Management Treatment is defined as symptomatic and supportive, as no specific antidote is known for the combination; hospital monitoring is typically required.

Immediate medical help must be sought for any suspected overdose, particularly if symptoms involve trouble breathing or a loss of consciousness. Pediatric populations are noted to have increased susceptibility to CNS excitation and respiratory depression following overdose. Official management procedures may include an ECG and activated charcoal in the early stages, as part of the overall supportive care strategy.

Therapeutic Uses of Ascoril-D Plus

What Ascoril-D Plus Treats: Main Uses and Benefits

The medication is commonly used for symptomatic relief in clinical situations marked by a concurrent cluster of upper respiratory symptoms, providing supportive benefit that helps ease the overall burden of acute discomfort. It is commonly used when short-term symptomatic assistance may be needed during common illness or allergic episodes. The combination formulation is considered relevant for easing symptoms that cluster into patterns requiring supportive management.

The formulation is relevant for managing nasal congestion, stuffiness, and blockage, alongside persistent, non-productive cough, and symptoms characteristic of allergic rhinitis such as runny nose and sneezing.

“The combined therapeutic approach is relevant in contexts involving heightened systemic burden where symptoms may create noticeable functional strain.”

Relief Domains

Ascoril-D Plus is applied in addressing the dry cough reflex and may assist with easing symptoms related to nasal obstruction while helping to control allergic manifestations. The preparation supports general well-being during symptomatic phases by assisting with maintaining functional stability.

Quick Fact: Relevant for Managing Dry Cough, Congestion, and Allergic Symptoms

Regulatory References

  1. DailyMed NIH overview of Dextromethorphan, Phenylephrine, and Triprolidine uses

Eligibility and Restrictions for Use

Official Eligibility Profile

The eligibility profile for Ascoril-D Plus (a combination of Dextromethorphan, Triprolidine, and a sympathomimetic decongestant) is strictly defined by regulatory contraindications and population restrictions associated with its active components.

Classification Population or Condition
ABSOLUTELY CONTRAINDICATED Children under 6 years of age (unfavorable risk-benefit balance).
Patients using Monoamine Oxidase Inhibitors (MAOIs) within 14 days (risk of severe interaction).
Patients with severe hypertension (high blood pressure) or severe coronary artery disease (due to the decongestant component).
Patients with severe hyperthyroidism or known hypersensitivity to any ingredient.
USE WITH CAUTION/NOT RECOMMENDED Pregnant and breastfeeding women (use only if clearly necessary and advised by a physician).
Older adults (age 65+) (increased susceptibility to side effects).
Patients with hepatic or renal impairment (requires medical review and possible dose adjustment).
Patients with pre-existing conditions like glaucoma, diabetes mellitus, or problems causing urinary retention.

Regulatory documents establish these clear non-eligibility rules, preventing use in populations where the risk is considered unacceptable, such as infants, individuals with severe cardiovascular instability, or those taking interacting medications.

What should I know about interactions with other medicines?

This product contains three active components: an antihistamine (Chlorpheniramine), a cough suppressant (Dextromethorphan), and a nasal decongestant (Phenylephrine). The combination of these ingredients leads to several important drug interactions.

Contraindicated and Restricted Combinations

Monoamine Oxidase Inhibitors (MAOIs): Use with or within 14 days of stopping MAOIs (such as Isocarboxazid, Phenelzine, Selegiline, or Tranylcypromine) is strictly restricted. This combination carries a significant risk of a life-threatening condition called Serotonin Syndrome (due to Dextromethorphan) or Hypertensive Crisis (due to Phenylephrine).

Central Nervous System (CNS) Depressants: Alcohol, sedatives, tranquillizers, anti-anxiety medicines (e.g., Alprazolam, Clonazepam), and certain other cough medicines should be avoided. Co-administration can significantly enhance drowsiness, dizziness, and sedation.

Other Significant Interactions

  • Antihypertensives (High Blood Pressure Medicines): Phenylephrine can counteract the effect of medicines used to control high blood pressure, leading to a reduction in their effectiveness and a potential abrupt increase in blood pressure.
  • Cardiac Medicines: The risk of an irregular heartbeat or heart attack may be increased when taken with heart failure medicines like Digoxin.
  • Other Sympathomimetics: Combining with other sympathomimetic agents, including certain antidepressants (e.g., Tricyclic Antidepressants, appetite suppressants, amphetamine-like psychostimulants), can raise blood pressure and increase the risk of adverse cardiovascular events.
  • Phenytoin and Ergot-containing Medicines: Concomitant use with Phenytoin (an anti-seizure medicine) or Ergot derivatives is advised against due to the potential for increased toxicity.

Mechanism of Action

Mechanism of Action

The combined physiological effects of this formulation arise from three distinct mechanistic domains. The antitussive action of Dextromethorphan is achieved centrally by modulating neural activity at Sigma-1 (sigma1) and NMDA receptors within the brainstem's cough center. This receptor interaction alters the excitability of local neurons, modulating the efferent signaling pathway and leading to the modulation of the central nervous system signals that initiate the cough reflex.

The decongestant effect is mediated by Phenylephrine, an agonist that binds to Alpha-1 (alpha1) adrenergic receptors on vascular smooth muscle. This alpha1 agonism initiates vasoconstriction in the nasal mucosa, which decreases the volume of blood and fluid contained within the local microvasculature, leading to a decrease in mucosal fluid accumulation and local tissue volume.

Finally, the Chlorpheniramine component operates through antagonism at the Histamine H1 receptors, blocking histamine-mediated increases in microvascular permeability. Concurrently, it engages secondary anticholinergic pathways that reduce glandular output, contributing to the diminished output of glandular fluid from the respiratory mucosa.

Dosage and Administration Information

How to Use Ascoril-D Plus: Administration Guidelines

Ascoril-D Plus is a fixed-dose combination (FDC) preparation delivered as an oral liquid (syrup). The instructions below describe the correct procedural administration and standardized dosing for combination cold products containing an antitussive and a decongestant.

Route and Preparation

  • Route of Administration: The syrup is intended exclusively for oral administration; it must be swallowed.
  • Preparation Requirement: The bottle must be shaken well before measuring each dose to ensure the active ingredients (Dextromethorphan, Phenylpropanolamine, Triprolidine, and Menthol) are evenly distributed.
  • Measurement: To ensure the proper volume is administered, doses must be measured using a calibrated measuring device (such as a cup or spoon provided with the medicine), not a standard household spoon.

Standard Dosing and Frequency

Treatment is intended for short-term symptomatic use, with a defined maximum dose and frequency that must not be exceeded.

Population Dose Per Administration Maximum Frequency Maximum Daily Dose
Adults and Children 12 years and older 10 mL Every 4 to 6 hours Not to exceed 4 doses in 24 hours
Children 6 to under 12 years of age 5 mL Every 4 to 6 hours Not to exceed 4 doses in 24 hours

Use Conditions and Special Populations

  • Timing: The medicine may be taken with or without food; taking it with food may help minimize the chance of stomach upset.
  • Duration of Use: Do not use this product for longer than 7 days unless advised to do so by a healthcare provider.
  • Pediatric Use: Use in children under two years of age is not recommended or requires specific medical guidance due to the increased sensitivity of this age group to the active ingredients. Dose adjustment may also be required for older adults (geriatric patients) and those with impaired organ function.

Recent Clinical Evidence

Recent Clinical Evidence Overview

This section summarizes the available research concerning the component compounds (Antihistamine X and Decongestant Y) often found in complex cough and cold formulations. Clinical studies primarily focus on the effects of these active pharmaceutical ingredients on common symptoms associated with the common cold and upper respiratory allergies.

Efficacy in Symptom Relief

Studies have investigated the effects of Antihistamine X on nasal discharge and sneezing. Research across multiple trials has reported a measurable change in these symptom severity scores compared to placebo in adult and adolescent populations. The component Decongestant Y was evaluated for its potential to reduce nasal congestion, with clinical data showing a temporary reduction in resistance within the nasal passages shortly after administration.

Functional Outcomes and Limitations

Trials evaluating these combinations commonly use patient-reported outcomes, such as the total symptom score, as their primary endpoint. While some participants report an overall improvement in comfort, findings regarding the impact on sleep quality or daily functioning remain mixed and require further investigation. Evidence does not currently establish a causal link between these components and the prevention of secondary infections or long-term complications.

Safety Data Reporting

Safety data gathered during post-market surveillance and clinical trials indicate that the components are generally well-tolerated. The most frequently reported adverse events include drowsiness associated with Antihistamine X and occasional restlessness or mild blood pressure changes attributed to Decongestant Y. Specific suitability questions regarding treatment should always be discussed with a qualified healthcare professional.

Frequently Asked Questions (FAQ)

Common questions about Ascoril-D Plus (FAQ)

Q: Are there any common over-the-counter medicines that should be avoided when using Ascoril-D Plus?

Official product information advises against combining this medicine with other over-the-counter products that contain similar active ingredients. Specifically, this includes other sympathomimetic drugs (stimulants), appetite suppressants, and CNS depressants (medicines that cause drowsiness). Combining these types of medicines can lead to enhanced side effects or potentially dangerous interactions.

Q: Is Ascoril-D Plus considered safe for use in children?

Official labeling states that the medication is contraindicated (should not be used) in children under 6 years of age due to an unfavorable risk-benefit balance in this population. Official information indicates that use is allowed only for children aged 6 to under 12 years. Parents should also be aware that excitement or irritability may be a noted side effect in pediatric patients.

Q: How does Ascoril-D Plus relate to other common cold and cough medicines?

According to official drug classifications, Ascoril-D Plus is a Fixed-Dose Combination (FDC) preparation. This means it combines an antitussive (cough suppressant), a decongestant (for nasal blockage), and a first-generation antihistamine into one solution. This combination is designed to provide comprehensive relief for the cluster of symptoms associated with the common cold.

Q: What is the main function of the 'D' component in Ascoril-D Plus?

The letter 'D' in this type of preparation typically highlights the inclusion of a decongestant ingredient, which in this case is Phenylpropanolamine. This component works to constrict the blood vessels in the nasal passages, helping to reduce swelling and relieve congestion.

Q: Is it common for Ascoril-D Plus to cause dizziness?

Yes, dizziness is a reported Central Nervous System (CNS) effect associated with the active ingredients, particularly the cough suppressant and the first-generation antihistamine. Official drug information lists side effects such as drowsiness, sedation, lightheadedness, and dizziness as commonly experienced effects.

Q: What is the difference between a suppressant and an expectorant in cough medicine?

The difference lies in their mechanism of action. A cough suppressant (or antitussive) like Dextromethorphan works on the cough center in the brain to reduce the urge to cough. In contrast, an expectorant works by increasing fluid production in the respiratory tract to thin and loosen mucus, helping the patient clear the airways.

Q: Does the use of Ascoril-D Plus have any restrictions concerning driving or operating machinery?

Due to the possibility of experiencing side effects such as drowsiness, dizziness, or visual changes, official patient information generally advises caution. Official patient information includes a general caution regarding activities that require mental alertness, such as driving or operating heavy machinery, until an individual is aware of how the medicine affects them.

Q: What should a person do if they suspect they have used too much Ascoril-D Plus?

Overdosing on the components in this medication carries a serious risk of severe Central Nervous System (CNS) depression and respiratory difficulties. Official guidance indicates that a suspected overdose requires immediate emergency medical attention due to this risk.

Q: Does Ascoril-D Plus interact with common herbal supplements?

Regulatory documents caution against potential interactions between the decongestant component and certain herbal preparations. Specifically, regulatory documents note caution for combinations with herbal supplements that act as stimulants or possess appetite-suppressing effects, as combining them may lead to additive side effects.

Q: Are there any known interactions between Ascoril-D Plus and caffeine?

Official warnings advise caution when combining this medication with Central Nervous System (CNS) stimulants such as caffeine. The decongestant component is a sympathomimetic agent, and consuming additional stimulants may lead to enhanced effects on the cardiovascular system, such as increased heart rate or blood pressure.

How should Ascoril-D Plus be stored and disposed of?

Official Storage and Disposal Requirements

Regulatory labeling dictates specific conditions for storing and disposing of Ascoril-D Plus Syrup to maintain product stability and safety. This medication must be stored in a cool and dry place, typically maintained at standard room temperatures (20 C to 25 C).

Storage Controls:

Condition Requirement
Temperature Store at room temperature.
Protection Protect from direct sunlight, heat, and moisture.
Container Keep in the original container, tightly closed.

Crucially, the medication must be kept strictly out of the reach of children and pets. To prevent accidental exposure or misuse, any unused or expired Ascoril-D Plus Syrup must be disposed of properly according to local guidelines; it should not be discarded in regular household trash or poured down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Ascoril-D Plus found in:

A-Z Index: